Ipamorelin has exactly one completed randomized, placebo-controlled trial in humans that tested it against a health outcome, and that trial did not beat placebo.[1] Everything else sold under the ipamorelin name, the muscle claims, the fat-loss claims, the anti-aging claims, rests on a different and much thinner body of evidence: small pharmacology studies that measured a hormone level rather than any clinical outcome. Marketing copy merges those two bodies of evidence constantly, as though a blood test and a patient outcome were the same kind of proof.
What the phase 2 trial tested
Beck and colleagues ran a multicenter, double-blind, placebo-controlled study of intravenous ipamorelin in 114 adults recovering from open or laparoscopic bowel resection surgery (ClinicalTrials.gov NCT00672074).[1] The logic was sound on paper: ghrelin-receptor stimulation drives gut motility, and postoperative ileus, the gut shutdown that follows abdominal surgery, is exactly the kind of problem a promotility drug should fix.
The result was a wash.
Median time to tolerating a solid meal: 25.3 hours with ipamorelin versus 32.6 hours with placebo.
The difference did not reach statistical significance (p = 0.15).
The trial’s own authors reported no significant difference between groups on the key endpoint or on any secondary efficacy measure.
Bottom line: the only trial that ever tested ipamorelin against a clinical outcome in humans found patients recovered gut function on roughly the same schedule whether they got the drug or saline.[1]
Read the paper’s limitations section and the numerical near-miss looks less surprising. The authors themselves flag that this was a small proof-of-concept study enrolling patients with “a broad range of underlying conditions,” not a single tightly matched surgical population.[1] A seven-hour edge in a mixed, 114-patient sample was never a strong bet to clear significance.
That is not a knock on the researchers. It is a reason to treat a single underpowered trial as inconclusive rather than as either a vindication or a death sentence for the compound.
What each ipamorelin study tested
Study | Design | Subjects | What it found |
|---|---|---|---|
Raun et al, 1998 | In vitro and animal pharmacology | Rat pituitary cells, rats, swine | GH release without the cortisol or ACTH rise seen with older secretagogues |
Gobburu et al, 1999 | Dose-escalation PK/PD trial | 8 healthy male volunteers per dose | Dose-dependent GH burst, peaking around 40 minutes |
Beck et al, 2014 | Phase 2 randomized, placebo-controlled trial | 114 post-surgical patients | No significant benefit over placebo on time to first tolerated meal |
The full published human record, plus the founding animal work.
Why ipamorelin releases growth hormone without the cortisol spike
The pharmacology is genuinely interesting, which is presumably why it got marketed so aggressively. Ipamorelin acts as a selective agonist at the ghrelin receptor, formally the growth hormone secretagogue receptor 1a, or GHS-R1a.[2] That receptor is the same one activated by the body’s natural hunger hormone, ghrelin, which is why appetite and gut motility keep showing up in its pharmacology.
What made it interesting in 1998 was the selectivity. Ipamorelin’s growth-hormone-releasing potency and its sparing of ACTH and cortisol, relative to older secretagogues, were first characterized in vitro in rat pituitary cells and in vivo in rats and swine, before any human trial examined the compound.[3] Raun and colleagues showed that in conscious swine, ipamorelin released growth hormone about as effectively as the older secretagogue GHRP-6, but unlike GHRP-6 and GHRP-2, it did not raise ACTH or cortisol above what GHRH alone produced, even at doses more than 200 times its own GH-releasing dose.[3]
Humans only got the growth hormone half of that story confirmed. Gobburu and colleagues ran a dose-escalation trial in healthy male volunteers and found that intravenous ipamorelin produced a dose-dependent burst of GH release peaking about 40 minutes after dosing, falling back to near baseline within a few hours.[4] Nobody has published a human trial replicating the cortisol and ACTH comparison that made the compound notable in swine.
This is the gap that marketing quietly papers over. Growth hormone secretion is not the same thing as muscle growth, fat loss, or a slower aging clock. GH’s downstream effects on lean mass and metabolism are well documented in other contexts, but that is a fact about growth hormone, not a fact anyone has demonstrated for ipamorelin specifically in a controlled trial. The muscle and longevity claims are extrapolated from GH physiology in general, then draped over a peptide whose only clinical trial tested a gut symptom and missed.
How much the trials used, and how it was given
Both published human studies dosed ipamorelin by intravenous infusion, not the subcutaneous injections most retail protocols recommend.
Gobburu’s healthy-volunteer trial used a five-step dose escalation, from 4.21 to 140.45 nanomoles per kilogram, infused over 15 minutes.[4]
Beck’s surgical trial used 0.03 milligrams per kilogram of body weight, given as an IV infusion twice daily for up to seven days or until hospital discharge.[1]
Neither study was designed to find an optimal or safe self-administered dose. They were designed to characterize how quickly the drug clears the body and how much GH it releases at a given concentration. Extrapolating either dosing schedule to a subcutaneous injection protocol bought online is not something either paper attempted, and it is not something this article will do either.
114 patients in ipamorelin's only completed efficacy trial PMID 25331030
What we know, and don’t know, about safety
The evidence here is thinner than the marketing suggests.
A narrative review of growth-hormone-axis peptides sold as research compounds, ipamorelin among them, reports that adverse effects across the class include appetite changes, dysglycemia and injection-site reactions, without isolating which effects are specific to ipamorelin.[5] In the one randomized ipamorelin trial, the overall adverse-event rate was similar between the drug and placebo groups (87.5 percent versus 94.8 percent).[5]
Nobody has published long-term safety data on ipamorelin at the repeated, self-administered doses common in bodybuilding or anti-aging protocols. The compound is not FDA-approved for any indication, and product bought outside a licensed compounding pharmacy carries none of the manufacturing oversight an approved drug does. That is a supply-chain risk layered on top of an efficacy question that is still, functionally, open.
Ipamorelin versus CJC-1295, its usual stacking partner
Ipamorelin is most often sold bundled with CJC-1295, and the two get talked about as if they were variations on the same idea, when the underlying pharmacology has almost nothing in common.
CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH). Teichman and colleagues showed it prolongs GH and IGF-I secretion in healthy adults by acting on the GHRH receptor, a completely different target from the ghrelin receptor ipamorelin engages.[6] Stacking the two is a plausible idea on paper, since GHRH and ghrelin-receptor signaling both feed into pituitary GH release through separate pathways, similar in spirit to combining two blood-pressure drugs that hit different points in the same system.
But plausible is not tested: no published human trial has combined ipamorelin and CJC-1295 to see whether the pairing does anything the compounds don’t do alone. For a deeper look at what CJC-1295 does and does not have behind it, see CJC-1295 and ipamorelin: real pharmacology, missing outcomes.
Ipamorelin also gets confused with the older GHRP-family secretagogues it was designed to improve on. GHRP-6 and GHRP-2 raise ACTH and cortisol along with growth hormone, the exact side effect ipamorelin was built to avoid.[3] Selectivity was the entire point of developing it. What selectivity has not bought it, so far, is a trial where that pharmacological advantage translated into a measurable clinical benefit.
The peptide it gets compared to least, and probably should not be, is sermorelin, an older GHRH analog with its own separate history and regulatory status. If you want a side-by-side of the two, ipamorelin vs sermorelin lays out where each one has a human trial and where it does not.
What would move this needle
Nothing currently registered would. A randomized trial testing ipamorelin against placebo on an endpoint that matches how it is marketed, lean body mass, strength, fracture healing, a validated biomarker of aging, does not exist in the public trial registries. The one trial that exists tested a different population for a different purpose, and it came up empty.
Peptides are not uniformly stuck at this stage. Some compounds in this space have accumulated a real, if uneven, human evidence base in specific applications. Ipamorelin has not gotten there. It has a well-characterized receptor mechanism, one human PK/PD study confirming the hormone effect that mechanism predicts, and one clinical trial that failed to turn that mechanism into a measurable patient benefit.
The shape of a trial that did not separate from placebo.
A properly powered trial testing ipamorelin against the outcomes it is sold for does not exist yet. Until one does, call the record what it is: one real efficacy trial, and it missed.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.. International journal of colorectal disease, 2014.
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.. The Journal of pharmacology and experimental therapeutics, 2009.
Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology, 1998.
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.. Pharmaceutical research, 1999.
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.. Frontiers in endocrinology, 2026.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 2006.
